Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units

被引:5
作者
EL-Shorbagy, Hanan I. [1 ,2 ]
Belal, Fathalla [1 ]
机构
[1] Mansoura Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Mansoura 35516, Egypt
[2] Suez Canal Univ, Fac Pharm, Dept Pharmaceut Analyt Chem, Ismailia, Egypt
关键词
Sofosbuvir; Ledipasvir; Covid; 19; HCV; Derivative/zero ratio spectrophotometry; First derivative spectrophotometry; HUMAN PLASMA APPLICATION; UPLC-MS/MS METHOD; RP-HPLC METHOD; SIMULTANEOUS QUANTIFICATION; METABOLITE; COMBINATION; VALIDATION; GS-331007; INFECTION; RIBAVIRIN;
D O I
10.1016/j.saa.2021.120623
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
An innovative simple, rapid and sensitive spectrophotometric method was developed for the simultaneous analysis of sofosbuvir (SOF) and ledipasvir (LED) in their combined dosage forms. Sofosbuvir with ledipasvir (SOF/LED) as a combined dosage form was tried at the pandemic COVID 19 crisis. This technique has the advantages of both zero order and first order spectrophotometry. The zero and first derivative amplitudes were measured at 274.2 nm for SOF (zero crossing point of LED in first derivative spectrum) and 314 nm for LED (zero crossing point of SOF in first derivative spectrum) over the concentration range of 2.0-50.0 mu g mL(-1) with coefficients of determination (R-2) > 0.9999 for both drugs and mean percentage recoveries of 100.25 +/- 1.61 and 99.85 +/- 0.99 for SOF and LED; respectively.This original method was validated according to ICH requirements and statistically compared to published comparison methods. This method was applied to estimate the average content and the uniformity of dosage units of SOF/LED combined dosage form according to British Pharmacopeia requirements.(c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:10
相关论文
共 50 条
[1]   Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study [J].
Abdallah, Ola M. ;
Abdel-Megied, Ahmed M. ;
Gouda, Amira S. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 143 :305-310
[2]  
Abdelwahab N.S., 2016, ANAL CHEM LETT, V6, P783, DOI DOI 10.1080/22297928.2016.1265468
[3]   Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products [J].
Abo-Talib, Nisreen F. ;
El-Ghobashy, Mohamed R. ;
Tammam, Marwa H. .
JOURNAL OF AOAC INTERNATIONAL, 2017, 100 (04) :976-984
[4]  
[Anonymous], 2005, Q2 R1 GUID
[5]  
[Anonymous], 2012, BRIT PHARM 2013, Vseventh
[6]   A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma [J].
Ariaudo, Alessandra ;
Favata, Fabio ;
De Nicolo, Amedeo ;
Simiele, Marco ;
Paglietti, Luca ;
Boglione, Lucio ;
Cardellino, Chiara Simona ;
Carcieri, Chiara ;
Di Perri, Giovanni ;
D'Avolio, Antonio .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 125 :369-375
[7]  
Ashok CV, 2016, Asian J Pharm Clin Res, V9, P61, DOI [10.22159/ajpcr.2016.v9-3.14616, DOI 10.22159/AJPCR.2016.V9-3.14616]
[8]  
Baker M. M., 2018, Annales Pharmaceutiques Francaises, V76, P16, DOI 10.1016/j.pharma.2017.07.005
[9]   Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) [J].
Bourliere, Marc ;
Bronowicki, Jean-Pierre ;
de Ledinghen, Victor ;
Hezode, Christophe ;
Zoulim, Fabien ;
Mathurin, Philippe ;
Tran, Albert ;
Larrey, Dominique G. ;
Ratziu, Vlad ;
Alric, Laurent ;
Hyland, Robert H. ;
Jiang, Deyuan ;
Doehle, Brian ;
Pang, Phillip S. ;
Symonds, William T. ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Marcellin, Patrick ;
Habersetzer, Francois ;
Guyader, Dominique ;
Grange, Jean-Didier ;
Loustaud-Ratti, Veronique ;
Serfaty, Lawrence ;
Metivier, Sophie ;
Leroy, Vincent ;
Abergel, Armand ;
Pol, Stanislas .
LANCET INFECTIOUS DISEASES, 2015, 15 (04) :397-404
[10]  
Devilal J., 2016, WORLD J PHARM PHARM, V6, P1312